Cargando…
Unleashing the power of NK cells in anticancer immunotherapy
Due to their physiological role in removing damaged cells, natural killer (NK) cells represent ideal candidates for cellular immunotherapy in the treatment of cancer. Thereby, the cytotoxicity of NK cells is regulated by signals on both, the NK cells as well as the targeted tumor cells, and the inte...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8843917/ https://www.ncbi.nlm.nih.gov/pubmed/34374809 http://dx.doi.org/10.1007/s00109-021-02120-z |
_version_ | 1784651369326575616 |
---|---|
author | Vogler, Meike Shanmugalingam, Senthan Särchen, Vinzenz Reindl, Lisa Marie Grèze, Victoria Buchinger, Leon Kühn, Michael Ullrich, Evelyn |
author_facet | Vogler, Meike Shanmugalingam, Senthan Särchen, Vinzenz Reindl, Lisa Marie Grèze, Victoria Buchinger, Leon Kühn, Michael Ullrich, Evelyn |
author_sort | Vogler, Meike |
collection | PubMed |
description | Due to their physiological role in removing damaged cells, natural killer (NK) cells represent ideal candidates for cellular immunotherapy in the treatment of cancer. Thereby, the cytotoxicity of NK cells is regulated by signals on both, the NK cells as well as the targeted tumor cells, and the interplay and balance of these signals determine the killing capacity of NK cells. One promising avenue in cancer treatment is therefore the combination of NK cell therapy with agents that either help to increase the killing capacity of NK cells or sensitize tumor cells to an NK cell-mediated attack. In this mini-review, we present different strategies that can be explored to unleash the potential of NK cell immunotherapy. In particular, we summarize how modulation of apoptosis signaling within tumor cells can be exploited to sensitize tumor cells to NK cell-mediated cytotoxicity. |
format | Online Article Text |
id | pubmed-8843917 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-88439172022-02-23 Unleashing the power of NK cells in anticancer immunotherapy Vogler, Meike Shanmugalingam, Senthan Särchen, Vinzenz Reindl, Lisa Marie Grèze, Victoria Buchinger, Leon Kühn, Michael Ullrich, Evelyn J Mol Med (Berl) Review Due to their physiological role in removing damaged cells, natural killer (NK) cells represent ideal candidates for cellular immunotherapy in the treatment of cancer. Thereby, the cytotoxicity of NK cells is regulated by signals on both, the NK cells as well as the targeted tumor cells, and the interplay and balance of these signals determine the killing capacity of NK cells. One promising avenue in cancer treatment is therefore the combination of NK cell therapy with agents that either help to increase the killing capacity of NK cells or sensitize tumor cells to an NK cell-mediated attack. In this mini-review, we present different strategies that can be explored to unleash the potential of NK cell immunotherapy. In particular, we summarize how modulation of apoptosis signaling within tumor cells can be exploited to sensitize tumor cells to NK cell-mediated cytotoxicity. Springer Berlin Heidelberg 2021-08-09 2022 /pmc/articles/PMC8843917/ /pubmed/34374809 http://dx.doi.org/10.1007/s00109-021-02120-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Review Vogler, Meike Shanmugalingam, Senthan Särchen, Vinzenz Reindl, Lisa Marie Grèze, Victoria Buchinger, Leon Kühn, Michael Ullrich, Evelyn Unleashing the power of NK cells in anticancer immunotherapy |
title | Unleashing the power of NK cells in anticancer immunotherapy |
title_full | Unleashing the power of NK cells in anticancer immunotherapy |
title_fullStr | Unleashing the power of NK cells in anticancer immunotherapy |
title_full_unstemmed | Unleashing the power of NK cells in anticancer immunotherapy |
title_short | Unleashing the power of NK cells in anticancer immunotherapy |
title_sort | unleashing the power of nk cells in anticancer immunotherapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8843917/ https://www.ncbi.nlm.nih.gov/pubmed/34374809 http://dx.doi.org/10.1007/s00109-021-02120-z |
work_keys_str_mv | AT voglermeike unleashingthepowerofnkcellsinanticancerimmunotherapy AT shanmugalingamsenthan unleashingthepowerofnkcellsinanticancerimmunotherapy AT sarchenvinzenz unleashingthepowerofnkcellsinanticancerimmunotherapy AT reindllisamarie unleashingthepowerofnkcellsinanticancerimmunotherapy AT grezevictoria unleashingthepowerofnkcellsinanticancerimmunotherapy AT buchingerleon unleashingthepowerofnkcellsinanticancerimmunotherapy AT kuhnmichael unleashingthepowerofnkcellsinanticancerimmunotherapy AT ullrichevelyn unleashingthepowerofnkcellsinanticancerimmunotherapy |